Home › Hepatitis C › NCT01644903

Proteogenomic Monitoring and Assessment of Liver Transplant Recipients

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Male and female recipients of all races, ≥18 years of age.
2. Patients undergoing primary or subsequent living or deceased donor liver transplantation.
3. Subject and/or guardian must be able to provide informed consent.
4. Subject and/or guardian must be able to comply with the study protocol.

Exclusion Criteria:

1\. Inability or unwillingness of a participant and/or guardian to provide informed consent.

About the study

This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages. CKD damage to the kidneys, AR and HCV all lower the body's ability to function properly. Early detection of these conditions could assist with successful treatment and possibly lead to less repeat organ transplants.

Sponsor: Northwestern University · Participants: 1,000 · Started: 2010-04

Contact the study team

Official record on ClinicalTrials.gov — NCT01644903

Locations in the U.S.

Conditions

• Hepatitis C
• Chronic Kidney Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.